


Loxapine

Cat. No.:	HY-17390		
CAS No.:	1977-10-2		
Molecular Formula:	C ₁₈ H ₁₈ ClN ₃ O		
Molecular Weight:	327.81		
Target:	5-HT Receptor; Dopamine Receptor; Bacterial		
Pathway:	GPCR/G Protein; Neuronal Signaling; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 33.33 mg/mL (101.67 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.0505 mL	15.2527 mL	30.5055 mL
	5 mM	0.6101 mL	3.0505 mL	6.1011 mL
	10 mM	0.3051 mL	1.5253 mL	3.0505 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.63 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.63 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.63 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Loxapine is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent^[1]
^[4].

IC₅₀ & Target

human 5-HT ₂	Human D ₄ Receptor	Human D ₁ Receptor	Human D ₂ Receptor
-------------------------	-------------------------------	-------------------------------	-------------------------------

In Vitro

In the presence of Loxapine, [³H]ketanserin binds to 5-HT₂ receptor in Frontal cortex of brain in human and bovine with K_i

value of 6.2 nM and 6.6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows: 5-HT₂≥D₄>>>D₁>D₂ in comparing competition experiments involving the human membranes^[1]. Loxapine (0-20 μM, 24 h or 72 h) reduces IL-1β secretion by LPS-activated mixed glia cultures, reduces IL-2 secretion in mixed glia cultures, and decreases IL-1β and IL-2 secretion in LPS-induced microglia cultures^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Loxapine (5 mg/kg; i.p.; daily for 4 or 10 weeks) decreases serotonin (S₂) but does not elevate dopamine (D₂) receptor numbers in the rat brain^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (150-175 g) ^[3]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection, daily for 4 or 10 weeks
Result:	Induced a very significant reduction (more than 50%) of serotonin (S ₂) receptor density after 4 weeks or 10 weeks of daily injection, but did not produce any significant increase in dopamine receptor density.

REFERENCES

- [1]. Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. *CNS Drugs*. 2013 Jun;27(6):479-89.
- [2]. Yang CY, et al. Loxapine, an antipsychotic drug, suppresses intracellular multiple-antibiotic-resistant *Salmonella enterica* serovar Typhimurium in macrophages. *J Microbiol Immunol Infect*. 2019 Aug;52(4):638-647.
- [3]. Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D₁, D₂, D₄ and serotonin 5-HT₂ receptor subtypes. *J Psychiatry Neurosci*. 1996 Jan;21(1):29-35.
- [4]. Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. *Eur Neuropsychopharmacol*. 2005 Jan;15(1):23-30.
- [5]. Lee T, et al. Loxapine and clozapine decrease serotonin (S₂) but do not elevate dopamine (D₂) receptor numbers in the rat brain. *Psychiatry Res*. 1984 Aug;12(4):277-85.
- [6]. Kalkman HO, et al. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. *Naunyn Schmiedebergs Arch Pharmacol*. 1997 Mar;355(3):361-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA